Eide Peter W, Moosavi Seyed H, Eilertsen Ina A, Brunsell Tuva H, Langerud Jonas, Berg Kaja C G, Røsok Bård I, Bjørnbeth Bjørn A, Nesbakken Arild, Lothe Ragnhild A, Sveen Anita
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway.
NPJ Genom Med. 2021 Jul 14;6(1):59. doi: 10.1038/s41525-021-00223-7.
Gene expression-based subtypes of colorectal cancer have clinical relevance, but the representativeness of primary tumors and the consensus molecular subtypes (CMS) for metastatic cancers is not well known. We investigated the metastatic heterogeneity of CMS. The best approach to subtype translation was delineated by comparisons of transcriptomic profiles from 317 primary tumors and 295 liver metastases, including multi-metastatic samples from 45 patients and 14 primary-metastasis sets. Associations were validated in an external data set (n = 618). Projection of metastases onto principal components of primary tumors showed that metastases were depleted of CMS1-immune/CMS3-metabolic signals, enriched for CMS4-mesenchymal/stromal signals, and heavily influenced by the microenvironment. The tailored CMS classifier (available in an updated version of the R package CMScaller) therefore implemented an approach to regress out the liver tissue background. The majority of classified metastases were either CMS2 or CMS4. Nonetheless, subtype switching and inter-metastatic CMS heterogeneity were frequent and increased with sampling intensity. Poor-prognostic value of CMS1/3 metastases was consistent in the context of intra-patient tumor heterogeneity.
基于基因表达的结直肠癌亚型具有临床相关性,但原发性肿瘤的代表性以及转移性癌症的共识分子亚型(CMS)尚不清楚。我们研究了CMS的转移异质性。通过比较317例原发性肿瘤和295例肝转移瘤的转录组谱,包括来自45例患者的多转移样本和14个原发-转移组,确定了亚型转化的最佳方法。在一个外部数据集(n = 618)中验证了相关性。将转移灶投射到原发性肿瘤的主成分上表明,转移灶中CMS1-免疫/CMS3-代谢信号减少,CMS4-间充质/基质信号增加,并受到微环境的严重影响。因此,定制的CMS分类器(可在R包CMScaller的更新版本中获得)采用了一种方法来消除肝组织背景的影响。大多数分类的转移灶为CMS2或CMS4。尽管如此,亚型转换和转移灶间的CMS异质性很常见,且随着采样强度的增加而增加。在患者内肿瘤异质性的背景下,CMS1/3转移灶的预后不良价值是一致的。